The impact of TIM3/Galectin-9 enrichment on the prognosis of DLBCL patients was analyzed based on the training cohort of GSE10846 (n = 412) and GSE53786 (n = 119) and validated by our cohort (n = 100). Here, LGALS9 is linked to diffuse large B-cell lymphoma.